Istvan E S, Deisenhofer J
Department of Biochemistry, Howard Hughes Medical Institute, University of Texas Southwestern Medical Center at Dallas, TX 75390-9050, USA.
Science. 2001 May 11;292(5519):1160-4. doi: 10.1126/science.1059344.
HMG-CoA (3-hydroxy-3-methylglutaryl-coenzyme A) reductase (HMGR) catalyzes the committed step in cholesterol biosynthesis. Statins are HMGR inhibitors with inhibition constant values in the nanomolar range that effectively lower serum cholesterol levels and are widely prescribed in the treatment of hypercholesterolemia. We have determined structures of the catalytic portion of human HMGR complexed with six different statins. The statins occupy a portion of the binding site of HMG-CoA, thus blocking access of this substrate to the active site. Near the carboxyl terminus of HMGR, several catalytically relevant residues are disordered in the enzyme-statin complexes. If these residues were not flexible, they would sterically hinder statin binding.
HMG-CoA(3-羟基-3-甲基戊二酰辅酶A)还原酶(HMGR)催化胆固醇生物合成中的关键步骤。他汀类药物是HMGR抑制剂,其抑制常数在纳摩尔范围内,能有效降低血清胆固醇水平,在高胆固醇血症治疗中被广泛应用。我们已确定人HMGR催化部分与六种不同他汀类药物复合的结构。他汀类药物占据了HMG-CoA结合位点的一部分,从而阻止该底物进入活性位点。在HMGR的羧基末端附近,几个与催化相关的残基在酶-他汀复合物中无序。如果这些残基不灵活,它们会在空间上阻碍他汀类药物的结合。